Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatments.

Gut 2000;46:443-446 ( April )


Leading article

Is liver fibrosis reversible?

Introduction

Liver fibrosis and cirrhosis result from the majority of chronic liver insults and represent a common and difficult clinical challenge of worldwide importance. At present, the only curative treatment for end stage cirrhosis is transplantation, but even in the developed world, the number of donor organs available and the clinical condition of the potential recipient limit the applicability of this technique. The alternative clinical course is one familiar to gastroenterologists---that of a progressive damage limitation exercise in which the complications of fibrosis and cirrhosis are treated with greater or lesser success. The development of fibrosis, and particularly cirrhosis, is associated with a significant morbidity and mortality. Thus, there is a considerable imperative to develop antifibrotic strategies that are applicable to liver fibrosis. Such an approach is attractive precisely because it is aimed at the final common pathological pathway of chronic liver disease, regardless of aetiology. However, because fibrotic liver disease may not present clinically until an advanced or cirrhotic stage, the possibility of reversing the fibrosis is an essential issue for developing therapeutic approaches.

Liver fibrosis represents the wound healing response of the liver, as such it demonstrates generic aspects that characterise tissue healing elsewhere in the body --- a wound healing response that is dynamic and has the potential to resolve without persistent scarring. This may seem at odds with the clinical impression that advanced fibrosis and cirrhosis are at best irreversible and at worst progressive. However, recent developments in our understanding of the process of hepatic fibrogenesis confirm that the process is dynamic with respect to both cell and extracellular matrix (ECM) turnover and suggest that a capacity for recovery from advanced cirrhosis and fibrosis is possible. Moreover, with the advent of effective antiviral therapies, biopsy documented examples of improvements in fibrosis and in some examples resolution, including that of cirrhotic change, are accumulating in the literature.1-4 To utilise these observations and establish the attributes required of an effective antifibrotic therapy, we need to understand the nature and origin of the fibrotic ECM, the methods by which the ECM is degraded and the essential processes which occur when fibrosis undergoes recovery with restoration of the normal liver architecture.

Nature and origin of fibrosis

Development of liver fibrosis entails major alterations in the both quantity and quality of hepatic ECM and there is overwhelming evidence that activated hepatic stellate cells (HSC, Ito, fat storing cell, or lipocyte) are the major producers of the fibrotic neomatrix.5  6 Hepatic stellate cells reside in the space of Disse and in normal liver are the major storage sites of vitamin A, stored in the cytoplasm as retinyl esters. Following chronic liver injury, HSC proliferate, lose their vitamin A and undergo a major phenotypical transformation to smooth muscle alpha -actin positive myofibroblasts (activated HSC) which produce a wide variety of collagenous and non-collagenous ECM proteins. Cirrhotic liver contains approximately six times more ECM overall than normal liver, and in the space of Disse collagen types III and V and fibronectin accumulate in early injury.7 In chronic injury here is increasing deposition of collagen types I and IV, undulin, elastin, and laminin.8 Hyaluronan, normally a minor component of the space of Disse, is increased more than eightfold9 and dermatan and chondroitin sulphate and heparan sulphate proteoglycans also increase. Although collagen types I, III, and IV are all increased, type I increases most and its ratio to types III and IV therefore increases.7  10-12 Culture studies have suggested that the neomatrix laid down in the space of Disse may itself contribute to the disease associated alterations in the phenotype of HSC, sinusoidal endothelial cells, and hepatocytes.13-16 With progressive injury ECM spurs link the vascular structures, ultimately resulting in the architecturally abnormal nodules that characterise cirrhosis.

Complete recovery from liver fibrosis would involve remodeling and breakdown of these multiple ECM components, with degradation of the predominant component, collagen I, being particularly important for recovery of normal liver histology. At present, the identities of the enzyme(s) that degrade the fibrillar collagens (collagens I and III) in the liver are unclear. The matrix metalloproteinases (MMP), a family of zinc dependent endoproteinases, have the capability to degrade these various ECM components and are expressed particularly by HSCs and Kupffer cells.17 The first discovered and best characterised interstitial collagenase in humans is MMP-1, which is widely expressed in human tissues including liver, but other human interstitial collagenases with a more limited cell expression include neutrophil collagenase (MMP-8) and collagenase 3 (MMP-13). The enzymes MMP-2 and MMP-14 have also recently been ascribed interstitial collagenolytic activity.18  19 However, studies in animal models and human liver fibrosis indicate that interstitial collagenolytic activity decreases in liver extracts in advanced fibrosis,20-24 which would promote net collagen deposition. There is increasing evidence that collagenase inhibition may arise from increased expression in fibrotic liver of endogenous MMP inhibitors, the tissue inhibitors of metalloproteinases (TIMPs). Expression of both TIMP-1 and -2  is increased in human and rat model fibrotic liver25-31 and in human liver the degree of TIMP-1 expression correlates with extent of fibrosis25 assessed by hydroxyproline content. Studies by our group and others25  27  31-33 indicate that activated HSC may be an important source of these TIMPs in injured liver. In rat models of liver fibrosis, TIMP-1 is expressed early in fibrogenesis before apparent collagen deposition.26 In contrast to the TIMPs, mRNA for interstitial collagenase (MMP-1 in humans, MMP-13 in rats) remains unaltered in human and rat liver as fibrosis develops.25  26  34 The resulting increase in TIMP:MMP ratio in liver may promote fibrosis by protecting deposited ECM from degradation by MMPs. However, other MMP inhibitory mechanisms might contribute to fibrosis. MMPs are released as inactive pro-enzymes, and an important regulatory step involves cleavage of the inhibitory N-terminal peptide to confer enzymatic activity.35 The means of proenzyme activation varies between different MMPs, but the protease plasmin is required for efficient activation of proMMP-1.36 Activated HSC may however inhibit plasmin synthesis in fibrotic liver through synthesis of plasminogen activator inhibitor-1 (PAI-1).37  38 Plasmin may have an important antifibrotic role, as studies of fibrosis in lung and kidney utilising PAI-1 and urokinase plasminogen activator knockout mice suggest that an increased PAI-1:urokinase ratio in tissues promotes fibrogenesis.39 In summary, activated HSC might produce a fibrogenic environment within the liver through a combination of ECM overproduction, diminished MMP activation and inhibition of active MMPs by TIMPs. The removal or inactivation of activated HSC from the liver is therefore likely to be a key process before recovery from fibrosis can occur.

Resolution of fibrosis

In clinical circumstances where an effective treatment for the underlying insult is available, remodeling of the scar tissue can occur and a return towards architectural normality has been documented even in advanced fibrosis and cirrhosis. This has been most clearly documented in autoimmune disease, but is paralleled by observations of haemochromatotic patients after venesection and patients with hepatitis B and C after successful interferon therapy.1-4 These observations are highly encouraging and suggest that the liver has a capacity to remodel scar tissue which, if harnessed and manipulated, would offer a novel therapeutic approach to the treatment of liver fibrosis. It is difficult, if not impossible to follow the cellular mechanisms mediating recovery in humans, as ethical considerations prevent serial biopsy samples from being taken from patients with liver disease and fibrosis which seems to be resolving clinically. However, recovery from fibrosis has been studied in rat models, which permit frequent sampling and control over the chronology and extent of the fibrotic lesion. Abdel-Aziz and colleagues40 examined reversibility of fibrosis in experimentally induced cholestasis in rats. Following bile duct ligation for three weeks, the typical features of bile duct proliferation and periportal fibrosis developed with a notable increase in hepatic mRNA for collagens I and IV. However, three weeks after relief of bile duct ligation (by reanastamosis of the bile duct to a jejunal loop), there was resorption of periportal fibrosis and the liver ECM returned virtually to normal, except for a persistence of collagen IV in sinusoids. Moreover mRNAs for collagen I and IV became virtually undetectable . We have recently examined spontaneous recovery from liver fibrosis in carbon tetrachloride treated rats.41 Rats treated for four weeks with intraperitoneal carbon tetrachloride developed established liver fibrosis with extensive intervascular bridging with collagen fibres. Carbon tetrachloride dosing then stopped and livers were examined at various times up to four weeks of recovery. After this time, histological analysis showed a noticeable dissolution of the collagenous fibrotic matrix and a return of liver structure to virtual normality. The hepatic mRNA content of TIMP-1 and -2 and procollagen I all dropped greatly in livers the first week of recovery which coincided with the most rapid phase of collagen degradation, as assessed by hydroxyproline content. A key finding was that interstitial collagenase activity increased in the liver homogenates during this time. The data support the hypothesis that TIMPs play a predominant role in regulating fibrosis by protecting fibrotic ECM from degradation by collagenase and possibly other MMPs. Another important observation was that there was prominent apoptosis of activated HSC during recovery, particularly in the first three days concomitant with the largest drop in hepatic TIMP and procollagen I mRNA. Apoptosis therefore effectively removed the activated HSC, which were overproducing ECM and TIMPs. This mechanism may also effect removal of "professional" ECM producing cells in other organs during wound healing and resolution of fibrosis. For example, Baker and colleagues42 showed that apoptosis removed surplus mesangial cells from glomeruli during resolution of mesangial proliferative nephritis and apoptosis also removes myofibroblasts during skin wound healing.43  44 Our more recent studies suggest that during progressive fibrotic liver injury both HSC mitosis and apoptosis increase---that is, turnover of these cells is increased, although proliferation predominates such that there is net increase in HSC numbers. During recovery, apoptosis becomes the overriding process with resulting net HSC loss from the liver.

There are relatively few studies of how apoptosis of HSC is controlled in the liver. HSC activated in culture undergo spontaneous apoptosis in vitro, which can be greatly increased by serum deprivation and fas ligand.41  45  46 Our recent studies show that a further cytokine present in injured liver, nerve growth factor, induces HSC apoptosis in culture. Mast cells, which become more abundant in fibrotic liver, are a rich source of nerve growth factor.47 The proapoptotic receptor fas and its ligand are also expressed by activated HSC.45 It is possible that persistence of HSC in fibrotic liver might therefore require undefined survival factors to offset the effects of these apoptotic stimuli, and removal of survival factors when liver injury ceases would then allow relatively rapid removal of HSC. Apoptotic signals in the liver might not be confined to soluble factors and the fibrotic neomatrix itself might render activated HSC susceptible to apoptosis. The role of cell-matrix interactions in regulating cell survival has most extensively been studied in epithelial cells in which absolute deprivation of contact with the ECM is a potent proapoptotic mechanism, a process that has been termed anoikis.48 A recent study has shown that blocking HSC attachment to plastic induces apoptosis,49 whereas data from our laboratory show that HSC cultured on plastic or collagen I are more susceptible to apoptosis induced by serum deprivation than HSC cultured on Matrigel, a basement membrane-like matrix which reduces HSC proliferation and activation. These final data raise the interesting idea that ECM degradation may result in HSC apoptosis rather than HSC apoptosis facilitating ECM degradation.

Although liver fibrosis in rats is reversible, the implications for recovery from cirrhosis in humans remain to be clarified. In our studies41 and those of Abdel-Aziz and coworkers,40 liver cirrhosis had not been achieved before recovery was initiated. Clearly a key question which can be tackled using rat models is: does liver fibrosis reach a point where it becomes irreversible, and if so what are the qualitative and quantitative differences in the liver structure compared with recoverable fibrosis? Several factors might dictate whether liver fibrosis can recover. Firstly, it is clear that recovery requires degradation of the existing ibrotic matrix, but this matrix may be modified to resist degradation as fibrosis progresses. Newly secreted collagen fibrils can be cross-linked by both tissue transglutaminase and lysyl oxidase pathways; the activity of both pathways is increased during liver fibrogenesis.50-52 Such cross-linking during maturation of collagen might reduce its susceptibility to collagenase.53 A recent report also suggests that tissue transglutaminase can be released onto ECM from apoptotic hepatocytes which are found in increased numbers in fibrotic liver.54 Mature ECM is also relatively rich in elastin; to date there are very limited data on the turnover of this important matrix protein in fibrosis. Secondly, recovery is unlikely if collagenolytic enzymes remain inactive following cessation of liver injury. The full range of enzymes having interstitial collagenase activities in liver still require identification. However, interstitial collagenase mRNA expression (MMP-1 in humans, MMP-13 in rats) is similar in normal compared with cirrhotic livers, and does not change during recovery in the rat model, even in the face of overt ECM degradation.25  26  41 Previous studies suggest that collagenase activity becomes deficient during evolution of liver fibrosis in animal models and in humans,20-24 and the studies described earlier suggest that this may be caused by TIMP overexpression. Continued inhibition of ECM degradation by TIMPs may block the ability to recover from fibrosis, even after removal of the injury. As activated hepatic stellate cells are an important source of both ECM and TIMPs, recovery from fibrosis might require either removal of the activated HSC population, as shown in rat models, or possibly the phenotypical reversal of stellate cell activation, a process yet to be observed in vivo. In non-recovering liver fibrosis activated HSC might persist as a result of a "memory" effect, possibly mediated by collagenous and non-collagenous components of the deposited fibrotic neomatrix, which either promote HSC activation or protect them from apoptotic stimuli.16  48  49  55

In summary, accumulating evidence suggests that liver fibrosis is reversible and that recovery from cirrhosis may be possible. Moreover, the application of cell and molecular techniques to models of reversible fibrosis are helping to establish the events and processes that are critical to recovery. It is anticipated that ultimately these approaches will lead to the development of effective antifibrotics, which harness or mimic the liver's capacity for reversal of fibrosis with resolution to a normal architecture.

Acknowledgments

JPI gratefully acknowledges the support of the Medical Research Council. JPI and RCB are in receipt of grant funding from the Wessex Medical Trust and Bayer AG.

R C BENYON J P IREDALE
Liver Fibrosis Group, Division of Cell and Molecular Medicine, Southampton University, Mail point 811, Southampton General Hospital, Tremona Road, Southampton SO16 6YD, UK

Correspondence to: Dr Iredale (email jpi@soton.ac.uk)

Footnotes

Leading articles express the views of the author and not those of the editor and editorial board.

Abbreviations

Abbreviations used in this article:
ECM, extracellular matrix; HSC, hepatic stellate cell; MMP, metalloproteinase; PAI, plasminogen activator inhibitor; TIMP, tissue inhibitor of metalloproteinases.

References

1.

Dufour JF, DeLellis R, Kaplan MM. Regression of hepatic fibrosis in hepatitis C with long-term interferon treatment.

Dig Dis Sci

1998;43:2573-2576[Medline].

2.

Dufour JF, DeLellis R, Kaplan MM. Reversibility of hepatic fibrosis in autoimmune hepatitis.

Ann Intern Med 1997;127:981-985[Medline].

3.

Niederau C, Fischer R, Sonnenberg,

et al. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985;313:1256-1262[Medline].

4.

Sobesky R, Mathurin P, Charlotte F,

et al. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group.

Gastroenterology

1999;116:378-386[Abstract/Full Text].

5.

Benyon RC, Arthur MJ. Mechanisms of hepatic fibrosis. J Pediatr Gastroenterol Nutr 1998;27:75-85[Medline].

6.

Burt AD. Cellular and molecular aspects of hepatic fibrosis. J Pathol 1993;170:105-114[Medline].

7.

Burt AD, Griffiths MR, Schuppan D,

et al. Ultrastructural localization of extracellular matrix proteins in liver biopsies using ultracryomicrotomy and immuno-gold labelling.

Histopathology 1990;16:53-58[Medline].

8.

Schuppan D. Structure of extracellular matrix in normal and fibrotic liver: collagens and glycoproteins. Semin Liver Dis 1990;10:1-10[Medline].

9.

Gressner AM, Haarmann R. Hyaluronic acid synthesis and secretion by rat liver fat storing cells (perisinusoidal lipocytes) in culture.

Biochem Biophys Res Commun 1988;151:222-229[Medline].

10.

Hahn EG, Wick G, Pencev DT,

et al. Distribution of basement membrane proteins in normal and fibrotic human liver: collagen type IV laminin and fibronectin.

Gut

1980;21:63-71[Abstract].

11.

Rojkind M, Giambrone M-A, Biempica L. Collagen types in normal and cirrhotic liver. Gastroenterology 1979;76:710-719[Medline].

12.

Seyer JM, Huherson ET, Kang AH. Collagen polymorphism in normal and cirrhotic human liver.

J Clin Invest

1977;59:241-248[Medline].

13.

McGuire RF, Bissell DM, Boyles J,

et al. Role of extracellular matrix in regulating fenestrations of endothelial cells isolated from normal rat liver.

Hepatology

1992;15:989-997[Abstract].

14.

Bissell DM, Caron JM, Babiss LE,

et al. Transcriptional regulation of the albumin gene in cultured rat hepatocytes. Role of basement-membrane matrix.

Mol Biol Med

1990;7:187-197[Medline].

15.

Bissell DM, Arenson DM, Maher JJ,

et al. Support of cultured hepatocytes by a laminin-rich gel.

J Clin Invest

1987;79:801-812[Medline].

16.

Friedman SL, Roll FJ, Boyles J,

et al. Maintenance of differentiated phenotype of cultured rat hepatic lipocytes by basement membrane matrix.

J Biol Chem

1989;264:10756-10762[Abstract].

17.

Arthur MJP. Matrix degradation in liver: A role in injury and repair.

Hepatology

1997;26:1069-1071[Medline].

18.

Ohuchi E, Imai K, Fujii Y,

et al. Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules.

J Biol Chem 1997;272:2446-2451[Abstract/Full Text].

19.

Aimes RT, Quigley JP. Matrix metalloproteinase-2 is an interstitial collagenase---inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments.

J Biol Chem 1995;270:5872-5876[Abstract/Full Text].

20.

Perez-Tamayo R, Montfort I, Gonzalez E. Collagenolytic activity in experimental cirrhosis of the liver.

Exp Mol Pathol 1987;47:300-308[Medline].

21.

Okazaki I, Maruyama K. Collagenase activity in experimental hepatic fibrosis.

Nature

1974;252:49-50[Medline].

22.

Maruyama K, Feinman L, Fainsilber Z,

et al. Mammalian collagenase increases in early alcoholic liver disease and decreases with cirrhosis.

Life Sci 1982;30:1379-1384[Medline].

23.

Montfort I, Perez-Tamayo R. Collagenase in experimental carbon tetrachloride cirrhosis of the liver.

Am J Pathol 1978;92:411-420[Medline].

24.

Takahashi S, Dunn MA, Seifter S. Liver collagenase in murine schistosomiasis.

Gastroenterology 1980;78:1425-1431[Abstract].

25.

Benyon RC, Iredale JP, Goddard S,

et al. Expression of tissue inhibitor of metalloproteinases-1 and -2 in increased in fibrotic human liver.

Gastroenterology 1996;110:821-831[Abstract].

26.

Iredale JP, Benyon RC, Arthur MJP,

et al. Tissue inhibitor of metalloproteinase-1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis.

Hepatology 1996;24:176-184[Abstract].

27.

Iredale JP, Goddard S, Murphy G,

et al. Tissue inhibitor of metalloproteinase-1 and interstitial collagenase expression in autoimmune chronic active hepatitis and activated human hepatic lipocytes.

Clin Sci 1995;89:75-81[Medline].

28.

Zhang K, Rekhter MD, Gordon D,

et al. Myofibroblasts and their role in lung collagen gene expression during pulmonary fibrosis---A combined immunohistochemical and in situ hybridization study.

Am J Pathol 1994;145:114-125[Medline].

29.

Kossakowska AE, Edwards DR, Lee SS,

et al. Altered balance between matrix metalloproteinases and their inhibitors in experimental biliary fibrosis.

Am J Pathol 1998;153:1895-1902[Abstract/Full Text].

30.

Lichtinghagen R, Breitenstein K, Arndt B,

et al. Comparison of matrix metalloproteinase expression in normal and cirrhotic human liver.

Virchows Arch 1998;432:153-158[Medline].

31.

Knittel T, Mehde M, Kobold D,

et al. Expression patterns of matrix metalloproteinases and their inhibitors in parenchymal and non-parenchymal cells of rat liver: regulation by TNF-alpha and TGF-beta1.

J Hepatol 1999;30:48-60[Medline].

32. I

redale JP, Murphy G, Hembry RM,

et al. Human hepatic lipocytes synthesize tissue inhibitor of metalloproteinases-1 (TIMP-1): Implications for regulation of matrix degradation in liver.

J Clin Invest 1992;90:282-287[Medline].

33.

Herbst H, Wege T, Milani S,

et al. Tissue inhibitor of metalloproteinase-1 and -2 RNA expression in rat and human liver fibrosis.

Am J Pathol 1997;150:1647-1659[Medline].

34.

Milani S, Herbst H, Schuppan D,

et al. Differential expression of matrix-metalloproteinase-1 and -2 genes in normal and fibrotic human liver.

Am J Pathol 1994;144:528-537[Medline].

35.

Murphy G, Stanton H, Cowell S, et al. Mechanisms for pro matrix metalloproteinase activation.

APMIS

1999;107:38-44[Medline].

36.

Matrisian LM. The matrix-degrading metalloproteinases.

Bioessays 1992;14:455-463[Medline].

37.

Leyland H, Gentry J, Arthur MJP,

et al. The plasminogen-activating system in hepatic stellate cells.

Hepatology 1996;24:1172-1178[Abstract].

38.

Knittel T, Fellmer P, Ramadori G. Gene expression and regulation of plasminogen activator inhibitor type I in hepatic stellate cells of rat liver.

Gastroenterology 1996;111:745-754[Abstract].

39.

Carmeliet P, Collen D. Development and disease in proteinase-deficient mice: role of the plasminogen, matrix metalloproteinase and coagulation system.

Thromb Res 1998;91:255-285[Medline].

40.

Abdel-Aziz G, Lebeau G, Rescan PY,

et al. Reversibility of hepatic fibrosis in experimentally induced cholestasis in rat.

Am J Pathol 1990;137:1333-1342[Medline].

41.

Iredale JP, Benyon RC, Pickering J,

et al. Mechanisms of spontaneous resolution of rat liver fibrosis: hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors.

J Clin Invest 1998;102:538-549[Abstract/Full Text].

42. Baker AJ, Mooney A, Hughes J,

et al. Mesangial cell apoptosis: The major mechanism for resolution of glomerular hypercellularity in experimental mesangial proliferative nephritis.

J Clin Invest 1994;94:2105-2116[Medline].

43.

Darby I, Skalli O, Gabbiani G. Alpha-smooth muscle actin is transiently expressed by myofibroblasts during experimental wound healing.

Lab Invest 1990;63:21-29[Medline].

44.

Desmouliere A, Redard M, Darby I,

et al. Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar.

Am J Pathol 1995;146:56-66[Medline].

45.

Saile B, Knittel T, Matthes N,

et al. CD95/CD95L-mediated apoptosis of the hepatic stellate cell. A mechanism terminating uncontrolled hepatic stellate cell proliferation during hepatic tissue repair.

Am J Pathol

1997;151:1265-1272[Medline].

46.

Gong W, Pecci A, Roth S,

et al. Transformation-dependent susceptibility of rat hepatic stellate cells to apoptosis induced by soluble Fas ligand.

Hepatology 1998;28:492-502[Abstract/Full Text].

47.

Nilsson G, Forsberg NK, Xiang Z,

et al. Human mast cells express functional TrkA and are a source of nerve growth factor.

Eur J Immunol 1997;27:2295-2301[Medline].

48.

Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis.

J Cell Biol

1994;124:619-626[Abstract].

49.

Iwamoto H, Sakai H, Tada S,

et al. Induction of apoptosis in rat hepatic stellate cells by disruption of integrin-mediated cell adhesion.

J Lab Clin Med 1999;134:83-89[Medline].

50.

Mirza A, Liu SL, Frizell E,

et al. A role for tissue transglutaminase in hepatic injury and fibrogenesis, and its regulation by NF-kappaB.

Am J Physiol

1997;272:G281-G288[Medline].

51.

Ricard BS, Bresson HS, Guerret S,

et al. Mechanism of collagen network stabilization in human irreversible granulomatous liver fibrosis.

Gastroenterology 1996;111:172-182[Abstract].

52.

Carter EA, McCarron MJ, Alpert E,

et al. Lysyl oxidase and collagenase in experimental acute and chronic liver injury.

Gastroenterology

1982;82:526-534[Abstract].

53.

Vater CA, Harris-ED J, Siegel RC. Native cross-links in collagen fibrils induce resistance to human synovial collagenase.

Biochem J

1979;181:639-645[Medline].

54.

Piacentini M, Autuori F, Dini L,

et al. "Tissue" transglutaminase is specifically expressed in neonatal rat liver cells undergoing apoptosis upon epidermal growth factor-stimulation.

Cell Tissue Res

1991;263:227-235[Medline].

55.

Jarnagin WR, Rockey DC, Koteliansky VE,

et al. Expression of variant fibronectins in wound healing: Cellular sources and biological activity of the EIIIA segment in rat hepatic fibrogenesis.

J Cell Biol

1994;127:2037-2048[Abstract].

© 2000 by Gut

Site Topics

  • Frequently Asked Questions

    Some of our most commonly asked questions and our answers to them.

  • What Is Hepatitis C?

    Learn about the Hepatitis C Virus (HCV).

  • Hepatitis C Transmission

    Information about the transmission of Hepatitis C.

  • Hepatitis C Symptoms

    You'll find links to a comprehensive symptoms list, as well as various studies and discussions about Hepatitis C symptoms.

  • Hepatitis C Conventional Treatment

    Learn about the conventional medical treatments used to fight Hepatitis C.

  • Hepatitis C Medicines

    Numerous links to studies, info sheets, FAQs, and analysis of Ribavirin/Rebetron medicines.

  • Hepatitis C Alternative Therapies

    Alternative methods of treatment due to side effects and dissatisfication with current medical treatments.

  • Hepatitis C Natural Remedies

    A number of herbal products useful in the management of liver disease.

  • Hepatitis C Survivor Stories

    Stories from those having direct experience with hepatitis c.

  • Hepatitis Central News Signup

    Receive the latest news on hepatitis treatments, clinical trials, social issues and important breakthroughs.

  • Hepatitis C Genotypes

    Learn about Hepatitis C Genotypes and their variants.

  • Hepatitis C Doctors

    A state-by-state and worldwide reference listing physicians who treat HCV, including an email link to submit your physician for inclusion.

  • Hepatitis C Links

    Convenient links to other sites external to Hepatitis-Central.

  • Hepatitis C Forum External link

    A Bulletin Board for discussions on hepatitis, treatments, etc.

  • Hepatitis C Activism External link

    An easy way to get involved in urging our government to do more for Hepatitis C awareness and treatment research.

  • Hepatitis B

    Numerous links to various Hepatitis B related information, including transmission, symptoms and treatment.

  • Biopsy Information

    A comprehensive resource of information relating to the liver biopsy.

  • Cirrhosis

    Many discussions and analyses of cirrhosis, including causes, complications, pathology, symptoms, and much more.

  • Glossary

    Commonly used medical terms and definitions.

  • Lab Tests

    What they are and what they mean. Helps you interpret & understand all the various hepatitis lab tests likely to be encountered.

  • Liver Cancer

    Liver Cancer/Hepatocellular Carcinoma studies, info sheets, FAQs, and analysis.

  • Liver Disease and Drugs

    An exhaustive list of links to studies, info sheets, FAQs, and analysis of the various drugs used to treat liver disease.

  • Top 5 Liver Supplements

    Provides information regarding the best known liver supporting supplements.

  • Top 5 Milk Thistles

    Provides information regarding the best known milk thistle supplements.

  • Viral Load

    Provides detailed information on how to analyze and interpret viral load numbers as well as a link to a convenient Viral Load Chart.

  • What is...?

    Learn more about various Hepatitis C related topics, including HCV, Ascites, Biopsies, and much more.

  • Hepatitis C Books

    Recommended reading for those interested in hepatitis information.

Advertisement(s)

Advertisement